DEAR VALUED MLABS CLIENTS:

Molecular testing is a valuable tool in the evaluation and personalized treatment of patients with malignancies and inherited conditions. Molecular tests may be ordered by the client, or may be generated as a result of a consultation.

As you are undoubtedly aware, many third party payers have instituted stringent requirements that they provide a PRIOR AUTHORIZATION for your patients in need of important molecular tests. Without a PRIOR AUTHORIZATION, your patient's claim for reimbursement of the test will be rejected and they will receive a significant bill from Michigan Medicine for this testing.

MLabs seeks to partner with our clients and our patients in achieving this PRIOR AUTHORIZATION. While many insurers require that the physician ordering the test apply for this PRIOR AUTHORIZATION, MLabs has worked to receive special exceptions that allow MLabs to submit the PRIOR AUTHORIZATION request on behalf of you and your patient (in most instances) so that this testing can be authorized, performed, and reimbursed without significant delay or co-payment required from our patients.

Applying for a PRIOR AUTHORIZATION requires that the insurance company is provided sufficient clinical information to support the clinical need for the test. MLabs hope that with this information, the PRIOR AUTHORIZATION can be submitted. Occasionally, MLabs personnel may contact your office for additional information if the insurance company requires it.

Effective September 4, 2018, MLabs will require that all requests for molecular tests are accompanied by the attached Molecular Diagnostic Clinical History Form AND a recent pathology report, relevant clinic encounter notes, or medical genetics consultation. MLabs will process the patient’s specimen to ensure stability of the specimen but may HOLD the specimen and NOT complete the test until all information for the PRIOR AUTHORIZATION is received.

THANK YOU, AS ALWAYS, FOR ENTRUSTING YOUR PATIENTS TO MLABS.